Advanced search
Publication Cover
Cancer Investigation Volume 34, 2016 - Issue 1
Submit an article Journal homepage
407
Views
27
CrossRef citations to date
0
Altmetric
Original Articles

Angiopoietin-2 May Be Involved in the Resistance to Bevacizumab in Recurrent Glioblastoma

Marianne LabussièreSorbonne Universités, Universite Pierre et Marie Curie, Centre de Recherche de l’Institut du Cerveau et de la Moelle épinière, Paris, France;Institut National de la Santé et de la Recherche Médicale, U 1127, Paris, France;Centre Nationale de la Recherche Scientifique, UMR 7225, Paris, France
,
Caroline CheneauSorbonne Universités, Universite Pierre et Marie Curie, Centre de Recherche de l’Institut du Cerveau et de la Moelle épinière, Paris, France;Institut National de la Santé et de la Recherche Médicale, U 1127, Paris, France;Centre Nationale de la Recherche Scientifique, UMR 7225, Paris, France
,
Claudia PrahstInstitut National de la Santé et de la Recherche Médicale, U 833, Paris, France;Collège de France, Paris, France
,
Jaime Gállego Pérez-LarrayaAssistance Publique-Hôpitaux de Paris, Groupe Hospitalier Pitié-Salpêtrière, Service de Neurologie 2, Paris, France
,
Patrizia FarinaAssistance Publique-Hôpitaux de Paris, Groupe Hospitalier Pitié-Salpêtrière, Service de Neurologie 2, Paris, France
,
Giuseppe LombardiAssistance Publique-Hôpitaux de Paris, Groupe Hospitalier Pitié-Salpêtrière, Service de Neurologie 2, Paris, France
,
Karima MokhtariSorbonne Universités, Universite Pierre et Marie Curie, Centre de Recherche de l’Institut du Cerveau et de la Moelle épinière, Paris, France;Institut National de la Santé et de la Recherche Médicale, U 1127, Paris, France;Centre Nationale de la Recherche Scientifique, UMR 7225, Paris, France;Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Pitié-Salpêtrière, Laboratoire de Neuropathologie R. Escourolle, Paris, France;OncoNeuroTek, Paris, France
,
Amithys RahimianOncoNeuroTek, Paris, France
,
Jean-Yves DelattreSorbonne Universités, Universite Pierre et Marie Curie, Centre de Recherche de l’Institut du Cerveau et de la Moelle épinière, Paris, France;Institut National de la Santé et de la Recherche Médicale, U 1127, Paris, France;Centre Nationale de la Recherche Scientifique, UMR 7225, Paris, France;Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Pitié-Salpêtrière, Service de Neurologie 2, Paris, France;OncoNeuroTek, Paris, France
,
Anne EichmannInstitut National de la Santé et de la Recherche Médicale, U 833, Paris, France;Collège de France, Paris, France
&
Marc SansonSorbonne Universités, Universite Pierre et Marie Curie, Centre de Recherche de l’Institut du Cerveau et de la Moelle épinière, Paris, France;Institut National de la Santé et de la Recherche Médicale, U 1127, Paris, France;Centre Nationale de la Recherche Scientifique, UMR 7225, Paris, France;Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Pitié-Salpêtrière, Service de Neurologie 2, Paris, France;OncoNeuroTek, Paris, FranceCorrespondence[email protected]
 show all
Pages 39-44 | Received 15 Jan 2015, Accepted 27 Aug 2015, Published online: 06 Jan 2016

References

  • Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005;438(7070):967–974.
  • Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285(21):1182–1186.
  • Salmaggi A, Eoli M, Frigerio S, Silvani A, Gelati M, Corsini E, et al. Intracavitary VEGF, bFGF, IL-8, IL-12 levels in primary and recurrent malignant glioma. J Neuro Oncol 2003;62(3):297–303.
  • Zhou YH, Tan F, Hess KR, Yung WK. The expression of PAX6, PTEN, vascular endothelial growth factor, and epidermal growth factor receptor in gliomas: relationship to tumor grade and survival. Clin Cancer Res 2003;9(9):3369–3375.
  • Schmidt NO, Westphal M, Hagel C, Ergun S, Stavrou D, Rosen EM, et al. Levels of vascular endothelial growth factor, hepatocyte growth factor/scatter factor and basic fibroblast growth factor in human gliomas and their relation to angiogenesis. Int J Cancer 1999;84(1):10–18.
  • Vredenburgh JJ, Desjardins A, Herndon JE, 2nd, Dowell JM, Reardon DA, Quinn JA, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 2007;13(4):1253–1259.
  • Vredenburgh JJ, Desjardins A, Herndon JE, 2nd, Marcello J, Reardon DA, Quinn JA, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007;25(30):4722–4729.
  • Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009;27(28):4733–4740.
  • Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Carpentier AF, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 2014;370(8):709–722.
  • Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 2014;370(8):699–708.
  • Batchelor TT, Reardon DA, de Groot JF, Wick W, Weller M. Antiangiogenic therapy for glioblastoma: current status and future prospects. Clin Cancer Res 2014;20(22):5612–5619.
  • Tabouret E, Boudouresque F, Barrie M, Matta M, Boucard C, Loundou A, et al. Association of matrix metalloproteinase 2 plasma level with response and survival in patients treated with bevacizumab for recurrent high-grade glioma. Neuro Oncol 2014;16(3):392–399.
  • Hamza MA, Mandel JJ, Conrad CA, Gilbert MR, Yung WK, Puduvalli VK, et al. Survival outcome of early versus delayed bevacizumab treatment in patients with recurrent glioblastoma. J Neuro Oncol 2014;119(1):135–140.
  • Bertolini F, Marighetti P, Shaked Y. Cellular and soluble markers of tumor angiogenesis: from patient selection to the identification of the most appropriate postresistance therapy. Biochim et Biophysica Acta 2010;1806(2):131–137.
  • Jubb AM, Harris AL. Biomarkers to predict the clinical efficacy of bevacizumab in cancer. Lancet Oncol 2010;11(12):1172–1183.
  • Kopetz S, Abbruzzese JL. Hidden biases in an observational study of bevacizumab beyond progression. J Clin Oncol 2009;27(10):1732–1733; author reply 1733.
  • Willett CG, Duda DG, di Tomaso E, Boucher Y, Ancukiewicz M, Sahani DV, et al. Efficacy, Safety, and Biomarkers of Neoadjuvant Bevacizumab, Radiation Therapy, and Fluorouracil in Rectal Cancer: A Multidisciplinary Phase II Study. J Clin Oncol. 2009.
  • Batchelor TT, Duda DG, di Tomaso E, Ancukiewicz M, Plotkin SR, Gerstner E, et al. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol 2010;28(17):2817–2823.
  • Chae SS, Kamoun WS, Farrar CT, Kirkpatrick ND, Niemeyer E, de Graaf AM, et al. Angiopoietin-2 interferes with anti-VEGFR2-induced vessel normalization and survival benefit in mice bearing gliomas. Clin Cancer Res 2010;16(14):3618–3627.
  • Rigamonti N, Kadioglu E, Keklikoglou I, Wyser Rmili C, Leow CC, De Palma M. Role of angiopoietin-2 in adaptive tumor resistance to VEGF signaling blockade. Cell Rep 2014;8(3):696–706.
  • Daly C, Eichten A, Castanaro C, Pasnikowski E, Adler A, Lalani AS, Papadopoulos N, et al.. Angiopoietin-2 functions as a Tie2 agonist in tumor models, where it limits the effects of VEGF inhibition. Cancer Res 2013;73(1):108–118.
  • Goede V, Coutelle O, Neuneier J, Reinacher-Schick A, Schnell R, Koslowsky TC, et al. Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy. Br J Cancer 2010;103(9):1407–1414.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.